New drug combo shows promise for tough blood cancers
NCT ID NCT01905813
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 23 times
Summary
This early-phase study tested a new drug called INCB040093, alone or with another drug itacitinib, in 121 adults with B-cell blood cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. The study also looked at whether the drugs could shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Birmingham, Alabama, United States
-
Study site
Jacksonville, Florida, United States
-
Study site
Ann Arbor, Michigan, United States
-
Study site
Rochester, Minnesota, United States
-
Study site
New York, New York, United States
-
Study site
Rochester, New York, United States
Conditions
Explore the condition pages connected to this study.